Published on 19 Oct 2021 on Benzinga
Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19.
Edesa reported that EB05 demonstrated mortality reductions in multiple patient groups beyond the initial findings.